DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious ischemic and vascular diseases. The company's mission is to improve the lives of individuals affected by these conditions through innovative therapies that aim to reduce ischemia. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. is incorporated under the laws of British Columbia, Canada.

The company's lead product candidate is DM199 (rinvecalinase alfa), a pharmaceutically active recombinant form of human tissue kallikrein-1 (rhKLK1). DM199 functions by enhancing blood flow and vascular health through increasing levels of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. This candidate is currently in clinical development for multiple indications, including preeclampsia (PE), fetal growth restriction (FGR), acute ischemic stroke (AIS), and chronic kidney disease (CKD). Additionally, DiaMedica is developing DM300, a recombinant human ulinastatin, in the preclinical stage for the treatment of inflammatory diseases such as acute pancreatitis.

Recent notable developments include the dosing of the first patients in a Phase 2 trial of DM199 for Fetal Growth Restriction in June 2026, and receiving FDA feedback on the DM199 Preeclampsia Nonclinical Program in the same month. In May 2026, the company announced reaching a 75% enrollment milestone in its ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial. Leadership includes Rick Pauls as President and CEO, and Julie Krop, MD, who was appointed Chief Medical Officer effective August 2025. DiaMedica Therapeutics Inc. is publicly traded on NASDAQ under the ticker DMAC and is included in the Russell 2000 and Russell 3000 indexes, with a market capitalization of approximately $400-411 million.